Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-1: SC0062 and Dapagliflozin in Type 1 Diabetes and Chronic Kidney Disease
NCT06072326Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of SC0062 in type 1 diabetes mellitus (T1D) and diabetic nephropathy (DN) (6 arms), sponsored by University Medical Center Groningen. Primary endpoint: Urine Albumin-Creatinine Ratio at 24 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
SC0062
03
Conditions
type 1 diabetes mellitus (T1D)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06072326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072326.